ADVERTISEMENT
2 /3 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Business

Affymetrix Will Acquire eBioscience

by Marc S. Reisch
December 5, 2011 | APPEARED IN VOLUME 89, ISSUE 49

Affymetrix has signed a definitive agreement to acquire eBioscience, a privately held maker of flow cytometry and immunoassay reagents, for $330 million in cash. Affymetrix, which supplies gene-sequencing instruments, says the deal will create new opportunities in areas such as immunology, oncology, cell biology, and diagnostics. eBioscience’s sales this year will be about $70 million, but Affymetrix CEO Frank Witney says eBioscience opens markets that represent “a nearly $3 billion annual opportunity.” The deal is Witney’s first at Affymetrix. He joined the firm in July after completing the sale of Dionex to Thermo Fisher Scientific.

X

Article:

This article has been sent to the following recipient:

Leave A Comment

*Required to comment